Nevro Corp. (NYSE:NVRO) released its quarterly earnings data on Monday. The medical equipment provider reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.11, Briefing.com reports. The business had revenue of $78.02 million during the quarter, compared to the consensus estimate of $77.75 million. Nevro Corp. had a negative net margin of 14.49% and a negative return on equity of 14.50%. The business’s revenue was up 40.8% compared to the same quarter last year. During the same period last year, the company posted ($0.31) earnings per share.

Nevro Corp. (NVRO) traded down 0.66% during trading on Monday, hitting $82.66. The stock had a trading volume of 721,860 shares. The firm has a 50 day moving average of $80.08 and a 200-day moving average of $85.48. The stock’s market cap is $2.42 billion. Nevro Corp. has a 12 month low of $65.82 and a 12 month high of $106.93.

In other news, CFO Andrew H. Galligan sold 7,500 shares of Nevro Corp. stock in a transaction on Monday, May 15th. The shares were sold at an average price of $75.30, for a total transaction of $564,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 12.10% of the company’s stock.

NVRO has been the topic of several analyst reports. B. Riley cut Nevro Corp. from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $108.00 to $85.00 in a research report on Tuesday, May 9th. Northland Securities reaffirmed a “buy” rating and issued a $96.00 price objective on shares of Nevro Corp. in a research report on Tuesday, May 9th. Zacks Investment Research cut Nevro Corp. from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. ValuEngine cut Nevro Corp. from a “hold” rating to a “sell” rating in a research report on Wednesday, May 24th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $102.00 price objective on shares of Nevro Corp. in a research report on Monday, July 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. Nevro Corp. presently has a consensus rating of “Buy” and a consensus target price of $103.10.

WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/07/nevro-corp-nysenvro-issues-quarterly-earnings-results-misses-estimates-by-0-11-eps.html.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Earnings History for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.